T1	Participants 569 595	143 patients at 30 centers
T2	Participants 316 536	patients with paroxysmal atrial fibrillation or flutter (PAF/PAFL) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide
